Corporate Update Call on Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Business Combination to Form Dogwood Therapeutics, Inc.

Oct 7, 2024 8:30 am EDT

Company Overview

Dogwood Therapeutics (Nasdaq DWTX) is a development-stage biotechnology company focused on advancing novel therapeutics for pain and fatigue illness.

Dogwood’s lead product, Halneuron®, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer related pain (CRP), and other pain indications. Halneuron is a small molecule that reduces pain transmission by blocking NAv 1.7, a sodium channel involved with the initiation and conduction of nerve impulses in the peripheral nervous system.

Dogwood is also pioneering the antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system.

View Management Team View Board of Directors

Recent Event

Corporate Update Call on Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Business Combination to Form Dogwood Therapeutics, Inc.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Investor Contact Information

Company

Dogwood Therapeutics, Inc.
44 Milton Avenue
Alpharetta, GA 30009

Investor Relations

IR@dwtx.com

Transfer Agent

Broadridge Corporate Issuer Solutions
P.O. Box 1342
Brentwood, NY 11717
T: 877-830-4936
shareholder@broadridge.com